DRAPER, Utah, Jan. 27, 2014 /PRNewswire/ -- Nutranomics,
Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company")
is pleased to announce that the Company has received an initial
purchase order from UNO International Corp. ("UNO"), a leading
health and natural products distributor in the Philippines.
The initial purchase order for 20,000 bottles of a Nutranomics
developed enzyme product is expected to be sold throughout
the Philippines by UNO's
established network of distributors.
"We are confident that this initial purchase order for one of
our extremely popular Nutranomics enzyme formulations will be the
first of many from UNO," stated Dr. Tracy
K. Gibbs, CEO of Nutranomics. "Following this
successful launch, we anticipate introducing several other
exclusive Nutranomics developed products to the 1000's of UNO
distributors all across the
Philippines."
UNO International Corp. is the largest Philippines-based company engaged in the
direct and multi-level distribution of health enhancing natural
products and other services. UNO's products include Glutathione
soaps as well as capsules and lotions, "8-in-1" coffee for
well-being and immune system support, "Ultima-C" non-acidic Vitamin
C, and "Fit Right" capsules with L-Carnitine, Green Tea and
Ampalaya.
About Nutranomics
Nutranomics is a publicly traded company engaged in research and
development of nutritional food products. In 1997, Nutranomics
produced and branded its own product line, and began to sell to the
retail outlets and to the public. Nutranomics has also produced
formulas for hundreds of other companies. Nutranomics' mission is
to increase human health and longevity through education and
self-awareness. The Company has sales representatives throughout
North America and Asia. Learn more about Nutranomics at
www.nutranomics.com.
For further information regarding Nutranomics, Inc., please
contact our investor relations representatives at
ir@nutranomics.com, or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements."
Statements in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
developing new products and operating as a development stage
company, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans,
competition in the industry in which we operate and market
conditions. These forward-looking statements are made as of the
date of this news release, and we assume no obligation to update
the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by applicable law, including the
securities laws of the United
States. Although we believe that any beliefs, plans,
expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors
should consult all of the information set forth herein and should
also refer to the risk factors disclosure outlined in the reports
and other documents we file with the SEC, available at www.sec.gov.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose,
treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
